跳至主要内容
临床试验/NCT00952939
NCT00952939已完成不适用

Prognostication of Uveal Melanoma by Fine Needle Aspiration (FNA) and Fluorescence in Situ Hybridization (FlSH)

Case Comprehensive Cancer Center1 个研究点 分布在 1 个国家目标入组 150 人开始时间: 2009年3月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
150
试验地点
1
主要终点
Number of patients that have Disease Free Survival (DFS) with primary uveal melanoma with and without high-risk genotypes

研究概览

简要总结

RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.

PURPOSE: This clinical trial is studying tumor samples in patients undergoing surgery or radiation therapy for primary melanoma of the eye.

详细描述

OBJECTIVES:

Primary

  • To establish the feasibility of using fine needle aspiration (FNA) and FISH to determine tumor genotype in patients with primary uveal melanoma.

Secondary

  • To characterize ophthalmic complication rate of FNA for FISH analysis in patients undergoing plaque radiotherapy.
  • To estimate disease-free survival in patients with and without tumor monosomy 3 and/or 8q amplification.
  • To explore the relationship between tumor monosomy 3 and 8q amplification and plasma levels of tumor immune escape and invasion biomarkers (e.g., circulating granulysin, beta2-microglobulin, autotoxin, lysophosphatidic acid, matrix metalloproteinase-7, tissue inhibitor of matrix metalloproteinase, and soluble E- cadherin).
  • To explore the psychological impact of prognostication in uveal melanoma.

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

结局指标

主要结局

Number of patients that have Disease Free Survival (DFS) with primary uveal melanoma with and without high-risk genotypes

时间窗: 2 years

DFS will be measured from the date of initial treatment to the date of documented recurrence or death. It will be summarized using the method of Kaplan and Meier.

次要结局

  • distribution of particular markers at specific timepoints(at baseline, multiple time points up to 2 years)
  • Number of patients with adverse events to determine ophthalmic complication rate of FNA for FISH analysis in patients undergoing plaque radiotherapy.(2 years)
  • The rate that sufficient tissue can be obtained by FNA.(2 yrs)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验